EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer

被引:9
作者
Asting, Annika Gustafsson [1 ]
Farivar, Ava [1 ]
Iresjo, Britt-Marie [1 ]
Svensson, Helena [1 ]
Gustavsson, Bengt [1 ]
Lundholm, Kent [1 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg, S-41345 Gothenburg, Sweden
关键词
COX-2; EGFR; Colorectal cancer; mRNA; Western blot; GROWTH-FACTOR RECEPTOR; CYCLOOXYGENASE-2; EXPRESSION; ASPIRIN USE; GLYCOSYLATION; CETUXIMAB; RISK; COX;
D O I
10.1186/1471-2407-13-511
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Cyclooxygenase (COX) and epidermal growth factor receptor (EGFR) activities promote progression of colorectal cancer. Combined treatment against these targets has not been more effective than single treatments alone. Therefore, our aim was to analyze relationships between COX and EGFR in peroperative colorectal tumor biopsies. Method: Tumor and colon mucosa tissue were collected at primary intended curative operations in patients according to well-recognized statistical distributions of tumor stages in colorectal cancer. COX-1, COX-2 and EGFR content in tumor and colon mucosa tissue were quantified by western blot and Q-PCR. Results: COX-2 protein appeared as two bands, one at 66 kDa in almost all tumor and mucosa samples and one at 74 kDa in 73% of the tumors and in 23% of the mucosa samples. Tumor COX-2 mRNA was not different from the content in mucosa samples, while COX-2 protein was increased in tumor tissue (p < 0.0003). A correlation between 74 kDa COX-2 protein and COX-2 mRNA occurred in tumor tissue, with significantly increasing COX-2 mRNA across tumor stages. EGFR mRNA content was lower in tumor tissue (p < 0.0001), while EGFR protein was similar in tumor and mucosa samples. COX-2 and EGFR proteins showed a positive correlation in mucosa, while a negative correlation occurred in tumor tissue. Tumor tissue with high COX-2 74 kDa protein lacked EGFR protein. Conclusion: Our present results are compatible with the theory that COX-2 and EGFR signalling pathways are inversely related in colorectal cancer tissue. This may explain why combinatorial clinical treatments have been less rewarding.
引用
收藏
页数:9
相关论文
共 37 条
[1]
EGFR isoforms and gene regulation in human endometrial cancer cells [J].
Albitar, Lina ;
Pickett, Gavin ;
Morgan, Marilee ;
Wilken, Jason A. ;
Maihle, Nita J. ;
Leslie, Kimberly K. .
MOLECULAR CANCER, 2010, 9
[2]
EGFR, HER-2 and COX-2 levels in colorectal cancer [J].
Antonacopoulou, A. G. ;
Tsamandas, A. C. ;
Petsas, T. ;
Liava, A. ;
Scopa, C. D. ;
Papavassiliou, A. G. ;
Kalofonos, H. P. .
HISTOPATHOLOGY, 2008, 53 (06) :698-706
[3]
Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo [J].
Axelsson, Hans ;
Lonnroth, Christina ;
Andersson, Marianne ;
Lundholm, Kent .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 37 (05) :1143-1152
[4]
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer [J].
Buchanan, F. Gregory ;
Holla, Vijay ;
Katkuri, Sharada ;
Matta, Pranathi ;
DuBois, Raymond N. .
CANCER RESEARCH, 2007, 67 (19) :9380-9388
[5]
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor [J].
Buchanan, FG ;
Wang, DZ ;
Bargiacchi, F ;
DuBois, RN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) :35451-35457
[6]
Cahlin C, 2005, INT J ONCOL, V27, P913
[7]
Chan Emily, 2011, Am J Clin Oncol, V34, P581, DOI 10.1097/COC.0b013e3181fe46a1
[8]
Analysis of cyclooxygenase expression in human colorectal adenomas [J].
Chapple, KS ;
Scott, N ;
Guillou, PJ ;
Coletta, PL ;
Hull, MA .
DISEASES OF THE COLON & RECTUM, 2002, 45 (10) :1316-1324
[9]
CYCLOOXYGENASE-1 AND CYCLOOXYGENASE-2 EXPRESSION IN RHEUMATOID SYNOVIAL TISSUES - EFFECTS OF INTERLEUKIN-1-BETA, PHORBOL ESTER, AND CORTICOSTEROIDS [J].
CROFFORD, LJ ;
WILDER, RL ;
RISTIMAKI, AP ;
SANO, H ;
REMMERS, EF ;
EPPS, HR ;
HLA, T .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) :1095-1101
[10]
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345